## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OIVID AFFROV	AL
OMB Number:	3235-028
Estimated average bure	den
hours per response	0.

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type	e Responses)																
Name and Address of Reporting Person   Ginocchio Paul				2. Issuer Name and Ticker or Trading Symbol Augmedix, Inc. [AUGX]								5.	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
C/O AUGMEDIX, INC., 111 SUTTER STREET, SUITE 1300  (Street)  SAN FRANCISCO, CA 94104				3. Date of Earliest Transaction (Month/Day/Year) 03/10/2022							X_Officer (give title below) Other (specify below)  CHIEF FINANCIAL OFFICER						
				4. If Amendment, Date Original Filed(Month/Day/Year)							)		6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person _Form filed by More than One Reporting Person				
(City) (State) (Zip)				Table I - Non-Derivative Securities Acqu							uritie	s Acquire	ired, Disposed of, or Beneficially Owned				
1.Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Yea		2A. Deemed Execution Date, i any (Month/Day/Year		Date, if	(Instr. 8		(/	4. Securities Acquir (A) or Disposed of (Instr. 3, 4 and 5)		f (D) Ow Tra	. Amount of Securities Bene Dwned Following Reported Transaction(s) Instr. 3 and 4)			Form:	7. Nature of Indirect Beneficial Ownership		
							Coo	de	V A	(A) or Amount (D)		Price			(1	or Indirect (I) (Instr. 4)	(Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if	(e.g., puts, ca				6. E (1	nired, Disposed of, or Benef options, convertible securit 6. Date Exercisable and Expiration Date (Month/Day/Year)		ties)	and Amount 8. Pricelying Derivers Securions		9. Number of Derivative Securities Beneficially Owned Following Reported	Owners Form o Derivat Securit Direct (	(Instr. 4)	
				Code	v	and 5)	(D	Е	Date Exercisable	Expiration Date	on	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)	(s) or Indir (I) (Instr. 4	
Employee Stock Option (right to buy)	\$ 2.48	03/10/2022		A		125,00			(1)	03/10/2	2032	Commo Stock		\$ 0	125,000	) D	
Report	ing Ov	vners															

	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
Ginocchio Paul C/O AUGMEDIX, INC. 111 SUTTER STREET, SUITE 1300 SAN FRANCISCO, CA 94104			CHIEF FINANCIAL OFFICER					

### **Signatures**

/s/ Todd Holvick, Attorney-in-Fact	03/11/2022
**Signature of Reporting Person	Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option is granted under the Augmedix, Inc. (the "Issuer") 2020 Equity Incentive Plan. The option will vest monthly in equal increments for four years starting on March 10, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date, and will be fully vested on March 10, 2026.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.